Loading stock data…
Health Catalyst, Inc (HCAT)
$1.70+0.01 (+0.59%)
Market ClosedLast close Sep 8
Health Catalyst, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Health Catalyst, Inc. in the Healthcare sector is trading at $1.70 with a market capitalization of $98M. Wall Street consensus targets $1.82 (4 analysts), implying a +7.4% move over the next 12 months. The stock is currently 53% below its 52-week high of $3.62, remaining 8.6% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +7.4% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $70.76M↓ | $74.68M↓ | $76.32M↓ | $80.72M↑ | $79.41M |
| Gross Profit | $35.46M↓ | $39.38M↑ | $37.82M↓ | $38.24M↑ | $36.23M |
| Operating Income | -$7.16M↓ | $3.26M↑ | -$17.51M↓ | -$8.32M↑ | -$17.02M |
| Net Income | -$111.03M↓ | -$91.03M↓ | -$22.23M↑ | -$40.98M↓ | -$23.74M |
Peer Comparison
JNJUNHPFE
Fundamentals
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations in the United States. The company operates in two segments: Technology and Professional Services. It offers ignite data and analytics platform that ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$98.28M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.63
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-192.01%
Volume
Today's trading volume
690,575
Recent News
Health Catalyst, GitLab, Elastic, and Marqeta Shares Plummet, What You Need To Know
A number of stocks fell in the afternoon session after Bloomberg reported that Anthropic’s preliminary second-quarter revenue topped $11.5 billion.
1 Unpopular Stock That Deserves a Second Chance and 2 We Avoid
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.
5 Must-Read Analyst Questions From Health Catalyst’s Q2 Earnings Call
Health Catalyst’s second quarter was marked by a notable decline in sales, which management attributed primarily to the ongoing impact of client migrations and a reduction in lower-margin services. The company’s decision to divest Vitalware, its revenue cycle management business, was described by CEO Ben Albert as necessary to focus on areas of highest conviction, despite the near-term revenue impact. Albert acknowledged the structural challenges facing health systems and emphasized that the div
Health Catalyst (HCAT) Q2 2026 Earnings Call Transcript
Company divests Vitalware for $147M, retires $160M debt amid platform migration.
HCAT Q2 Deep Dive: Vitalware Divestiture Reshapes Strategy Amid Revenue Decline
Healthcare data analytics company Health Catalyst (NASDAQ:HCAT) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, but sales fell by 12.7% year on year to $70.49 million. On the other hand, next quarter’s revenue guidance of $55.5 million was less impressive, coming in 10.7% below analysts’ estimates. Its non-GAAP profit of $0.04 per share was in line with analysts’ consensus estimates.